The PSD is a morphological and functional specialization of the postsynaptic membrane. This specialized signaling machinery is composed of 1,500-2,000 proteins 1,2 arranged in protein interactions that can be modulated by post-translation modifications [3] [4] [5] . A common regulatory mechanism to ensure that signaling components encounter their intracellular partners in the right place and time is the association of components in protein complexes 6, 7 . These interactions use protein scaffolds with specialized protein-interaction modules (protein domains) as a key mechanism to achieve specificity. A core feature of the PSD is the presence of a variety of scaffold molecules containing protein domains specialized in protein-protein interactions 8, 9 . A schematic view of PSD scaffolds describes three layers of scaffold proteins: a top layer composed of membrane-associated guanylate kinase (MAGUK)-family members that connect to glutamate receptors, a bottom layer of SHANK-family scaffolds and a middle connecting layer composed of disk large associated guanylate-associated protein (DLGAP) proteins. These three scaffold families may be considered fundamental organizers of the core protein-protein interaction machinery of the postsynaptic site [10] [11] [12] [13] . A number of components of the PSD have been linked to a plethora of brain diseases 1,14 . However, there is a lack of information on how these components associate in protein interaction networks and how these molecules might change their protein interactions through development and within different cellular contexts, where they might represent different functional pathways rather than only a single PSD component.
The PSD is a morphological and functional specialization of the postsynaptic membrane. This specialized signaling machinery is composed of 1,500-2,000 proteins 1,2 arranged in protein interactions that can be modulated by post-translation modifications [3] [4] [5] . A common regulatory mechanism to ensure that signaling components encounter their intracellular partners in the right place and time is the association of components in protein complexes 6, 7 . These interactions use protein scaffolds with specialized protein-interaction modules (protein domains) as a key mechanism to achieve specificity. A core feature of the PSD is the presence of a variety of scaffold molecules containing protein domains specialized in protein-protein interactions 8, 9 . A schematic view of PSD scaffolds describes three layers of scaffold proteins: a top layer composed of membrane-associated guanylate kinase (MAGUK)-family members that connect to glutamate receptors, a bottom layer of SHANK-family scaffolds and a middle connecting layer composed of disk large associated guanylate-associated protein (DLGAP) proteins. These three scaffold families may be considered fundamental organizers of the core protein-protein interaction machinery of the postsynaptic site [10] [11] [12] [13] . A number of components of the PSD have been linked to a plethora of brain diseases 1, 14 . However, there is a lack of information on how these components associate in protein interaction networks and how these molecules might change their protein interactions through development and within different cellular contexts, where they might represent different functional pathways rather than only a single PSD component.
Here we investigated the organization of the core-scaffold machinery of the PSD by immunoisolation of MAGUKs, DLGAPs and SHANKs at embryonic day 14 (E14), postnatal day 7 (P7), P14 and in adult mouse prefrontal cortex (PFC) and determined their association with in vivo protein interactors in physical complexes. We show that throughout development core-scaffolding components of the PSD have both shared and distinct interactors, which define a unique interactome before PSD maturation. We immunoisolated and determined protein complexes for interactors of PSD scaffolds, which enabled the total identification of 41 interactomes and 2,876 individual interactors. Using de novo coding mutations on exomesequenced parent-proband trio cohorts from a variety of brain and psychiatric disorders, we describe where mutations implicated in contributing to autism spectrum disorders (ASD), developmental delay (DD), intellectual disability (ID) and schizophrenia (SCZ) were distributed within protein interactomes. These results were integrated into a software platform that allows the visualization of disease risk factors within protein networks, and we provide examples of how highly connected components of the PSD signaling network disrupt protein-protein interactions associated with psychiatric and other complex brain disorders.
r e s o u r c e RESULTS First, we determined the developmental profile of PSD scaffold protein complexes. We isolated Dlg4, Dlgap1 and Shank3 in vivo protein interactomes at E14, P7, P14 and adult mouse prefrontal cortex (PFC). All of the immunopurified protein complexes were obtained by in vivo immunoisolation of the target protein using knockout and knockin mouse lines, anti-GST antibodies and reciprocate immunoprecipitations as controls (Online Methods). Protein complexes were fractionated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano-LC MS/MS; Fig. 1a ,b, Supplementary Table 1 and Online Methods). This developmental interactome of PSD scaffolds resulted in 1,085 in vivo protein interactors from 12 protein complexes in partially overlapping proteininteraction networks (Fig. 1a and Supplementary Table 1) . Although the roles of PSD scaffolds in the organization of protein interactions have been widely recognized, only a relatively small number of protein interactions have been reported. We extracted and manually curated protein interactions reported for Dlg4, Dlgap1 and Shank3, using the BioGRID 15 and Mentha 16 protein-protein interaction databases. We extracted protein interactions identified in human, mouse and rat and compared them to our protein-protein interaction data, considering the individual species in which protein interactions were reported or a combination of all three species. For protein complexes identified at different time points in development, we compared each developmental-stage-specific complex or the combination of all time points, for a total set of nonredundant interactions. For a majority of the reported protein complexes, approximately 90% of the nonredundant interactions reported had not been previously characterized, with the smallest percentage of such interactions in any one dataset being 70% in nonredundant and 56% in redundant interactions, in the case of Dlg4 (Fig. 1c, Supplementary Tables 1 and 2 and Supplementary Fig. 1 ) Moreover, these databases include a collection of protein interactions reported with a variety of methods, including direct and indirect assays. While direct methods show binary protein-protein interactions, indirect methods can also contain associations of proteins in larger, nonbinary interactions in which the reported proteins might not be directly interacting. Due to this, we analyzed the experimental methods used to characterize each of the previously reported interactions ( Supplementary Fig. 2 ). This enabled us to show that a majority of reported interactions were determined via indirect assays, while a lower proportion were shown using direct methods, such as yeast two-hybrid, co-crystallization studies or both.
The relationship between protein interactions and gene expression levels has been widely studied [17] [18] [19] . It has been proposed that tissuespecific proteins can interact with core cellular components and that universally expressed proteins (housekeeping proteins) can also interact with tissue-specific proteins 19 . This scenario has also been proposed for a number of PSD-specific proteins 19 . Therefore, it has been suggested that the biology of particular tissues might be better interpreted by the individual protein interactions rather than by the specific proteins expressed within a tissue 19 . However, these analyses compare the gene expressions of protein interactors through different tissues rather within the tissue in which the protein interaction occurs. Therefore, it is still not known whether the expression levels of protein interactors within protein complexes are better correlated when compared to the background of proteins expressed within the same tissue. Thus, we used the Brainspan database to obtain a developmental gene expression profile for the human orthologs of each protein present in scaffold complexes and compared their expression profiles at the corresponding human developmental stage: E14 in mice is roughly equivalent to the second trimester of pregnancy in humans; P7 is roughly equivalent to late-fetal or neonatal stages; P14 is equivalent to early childhood; adult mice are equivalent to young adult or adult humans.
For each protein complex, we considered three parameters: the number of proteins in the complex, the developmental period from which the complex was derived and the corresponding gene expression levels of those proteins involved in the complex. We generated pseudocomplexes by randomly sampling an equal number of proteins for each complex from a tissue-and development-period-specific background, and performed simulations to obtain an average sample correlation across each pseudocomplex, thus providing an empirical P value. Pseudocomplexes failed to produce an average sample correlation greater than observed in the protein complexes of interest ( Fig. 2a-d) , suggesting a significant correlation between protein complex composition and tissue expression. Moreover, no differences were observed along different developmental stages; we observed similar correlation levels for scaffold complexes at E14, P7, P14 and adult stages ( Fig. 2a-d) . Therefore, among brain genes with similar expression levels, protein interactions grouped in scaffold complexes were significantly more highly correlated ( Fig. 2a-d) , suggesting a tighter correlation and regulation of expression levels, within tissue, for protein-interacting partners.
We then determined the degree of similarity between scaffold complexes through development. We constructed a matrix plot and hierarchical clustering analysis of protein interactors for each individual protein complex and analyzed their shared interactors. While there was a general trend toward increasing similarity between complexes of a particular scaffold protein through development, the differences for any cluster at different developmental stages were not statistically significant (P = 0.0862). Moreover, while embryonic complexes (E14) clustered separately from other stages, postnatal and adult protein complexes for any given scaffold showed a greater overlap with each other than with complexes of a different scaffold protein at any other stage. This suggests a differential contribution of individual components of the scaffold machinery of the PSD in the clustering of protein interactions through mouse development ( Fig. 2e and Supplementary Table 1) .
Developmental organization of core PSD scaffold interactions
The clustering of PSD scaffolding complexes through development (Fig. 2e) indicated a differential association of Dlg4 and Dlgap1 complexes compared to Shank3 interactions (Fig. 2e) . Analysis of individual protein complexes showed that embryonic PFC contained a preassembly of the core-scaffold machinery of the PSD with disks large proteins (DLGs) associated with NMDA-receptor (NMDAR) subunits and DLGAP scaffolds. These top and middle layers of scaffolds were not associated with the lower layer composed by SHANK proteins (Fig. 1c and Supplementary Table 1) . We observed that Dlg4 and Dlgap1 protein complexes contained NMDAR subunits Grin1, Grin2b and Grin2d, together with top (Dlg1, Dlg2, Dlg3) and middle (Dlgap2, Dlgap3, Dlgap4 and Dlgap5) scaffolds. However, none of these protein complexes contained any member of the SHANK family of protein scaffolds, nor did Shank3 complexes contain any DLG-or DLGAP-family protein (Supplementary Table 1 ). Shank3 complexes showed an early developmental association with a different set of adaptor and scaffold proteins that are usually described in PSD fractions, such as Baiap2, Lrrc7, Shank1 and 2 and Homer1-3, which are not present in DLG or DLGAP protein complexes (Supplementary Table 1 ). Overall, this suggests a differential building of the corescaffold machinery of the PSD throughout development, in which © 2017 Nature America, Inc., part of Springer Nature. All rights reserved. r e s o u r c e the top and middle layers of the PSD connect to glutamate receptors as early as mouse E14, while the SHANK layer is still not a part of the core-scaffold machinery. However, at E14 this layer associates with a number of PSD signaling components that will be incorporated to the scaffold core at later stages, beginning at P7.
The protein domain landscape of scaffold interactomes Protein domains are considered basic units of biological function 6, 20 . Therefore, the protein domain composition and the molecular organization of protein domains may indicate the range of cellular functions within protein complexes. To analyze the set of protein functions integrated in the PSD throughout development, we determined the distribution of protein domains within protein complexes and their combinatorial interactions.
We first extracted and manually curated protein domains using the SMART 21 and Pfam 22 databases (Online Methods) and determined the (i) protein domain composition, (ii) protein domain enrichment and (iii) protein domain architectures in each protein complex (Fig. 3a-d Table 3 ). However, we observed a differential contribution of DLG, DLGAP and SHANK scaffolds to the protein domain composition of the PSD through development. Starting at the E14 stage, Dlg4 and Dlgap1 complexes began to incorporate GKAP, GuKc and PDZ domains to glutamate receptor-containing complexes (PBPe glutamate receptor; SMART SM00079; Fig. 3a and Supplementary Table 4), while Shank3 complexes provided a higher number of polyproline binding domains, such as SH3 and WH1 ( Fig. 3a  and Supplementary Table 4) . Moreover, while the top layer of scaffolds represented by Dlg4 incorporated an increasing number of glutamate receptors throughout development, the middle and lower scaffolds (Dlgap1 and Shank3) provided a variety of protein domains involved in second messenger signaling, cytoskeletal binding and enzymatic function (Fig. 3a and Supplementary Table 4) . In particular, we found an early enrichment in serine and threonine kinase domains in Shank3 complexes starting at P7. This indicates a developmental buildup of PSD functions organized by different members of PSD scaffolds using core protein-protein interaction domains to recruit functional modules to the PSD.
Moreover, analysis of the organization of protein domains (domain architectures) showed that the core protein interaction domains (SAM, PDZ, SH3, GuKc and ANK) were grouped in protein families containing multidomain architectures ( Fig. 3c and Supplementary Dataset 1) . These multidomain architectures serve as core-building components to associate a variety of domain combinations, including those involved in signaling mechanisms, and incorporate a larger number of scaffolds to the PSD (Fig. 3b,c and Supplementary Dataset 1) . The core-scaffolds provide the essential backbone to expand the PSD's functional capacity, resulting in the acquisition of enhanced signaling machinery with the capacity to modulate postsynaptic function throughout development.
Scaffold protein interactors
To expand the PSD protein interaction network, we first wanted to determine protein interactomes representing different regions of the network. Thus, we first clustered the developmental Dlg4-Dlgap1-Shank3 network ( Fig. 4a and Supplementary Table 5) , screened the clusters for specific antibodies directed against interactors from different functional groups and numbers of links (classed into 9 groups (degrees) based on number of links) within the scaffold network (Fig. 4a) r e s o u r c e r e s o u r c e the PSD, many of their interactors can also localize in different subcellular fractions (non-PSD). However, information about protein interactions corresponding to PSD or other subcellular fractions is lacking. Therefore, we also screened protein interactomes for this set of proteins in PSD and in non-PSD fractions. This latter fraction corresponded to PFC Triton X-100-soluble fractions 3 (Online Methods) and allowed us to discriminate between PSD-specific and nonspecific (non-PSD) interactions. We thus expanded the PSD protein interaction network with 15 scaffold interactors, to a total of 28 protein interactomes (Table 1 ) and 1,776 protein interactions (Supplementary Table 1 ). As observed for protein scaffolds, these sets of protein interactions were largely unreported in literature. A majority of the interactions that were previously reported were discovered using nonstoichiometric systems, which do not consider developmental WW  WH2  WH1  VIT  VWA  TYRKC  SORB  RAS  RAB  PX  RHOGAP  PUR  PP2AC  MIRO  LRRCT  LRRNT  LRR_TYP  LRR1  LRR4  LRR  LIM  VHP  L27  KISC  PH  IQ  SEC7  SEC14  IGC2  RHOGEF  HDC  GUKC  PDZ  SH3  TSP1  GPS  HORMR  GKAP  GELSOLIN  FN3  ENTH  EFH  DYNC  GED  FH2  DRF_FH3  DRF_GBD  DNAJ  RASGEFN  RASGEF  CNMP  DEP  CH  SPEC  CAP_GLY  C2  RASGAP  CNH  C1  S_TKC  BTB  BEACH  WD40  B41  FA  FERMC  ARM  ARFGAP  GIT  ARF  ANK  SAM  ADF  ACR  DISIN  14−3−3  FA58C  FBG  EGF  4.1M  LAMG   YWHAZ  YWHAQ  YWHAH  YWHAG  YWHAB  YWHAE  WASF1  SNAP91  RAPGEF4  RAP1A  RAB1  PURA  PPP3CB  PPP1CC  PPP3CA  PDE4B  LRRTM1  LGI1  LRRC15  KIF5A  KIF5C  ITIH4  IQGAP2  SYNE1  SPTBN1  SPTBN2  HOMER1  GSN  NBEA  GNB1  GNB2  FBXO41  LRRC7  ERBB2IP  MPDZ  PTK2  EPB4.1L1  EPB41L3  DSTN  DNAJC6  DLGAP4  DLGAP3  DLGAP1  DLGAP2  DIAPH1  DDN  CYLD  FARP1  KALRN  TRIO  DNM1  SYNGAP1  DAB2IP  RASAL2  CYTH3  IQSEC3  IQSEC1  IQSEC2  CNKSR2  MPRIP  MAPK3  MAPK1  CDK5  CAMK2G  CAMK2D  CAMK2A  CAMK2B  MINK1  TNIK  CIT  PRKCB  PRKCG  BTBD11  KCNA4  KCNA1  KCNA2  SPNA2  SHANK2  CASKIN1  SHANK1  SHANK3  DLG4  DLG3  DLG1  DLG2  BAIAP2  SH3KBP1  SORBS1  SORBS2  BAI2  BAI3  CTNND2  CTNND1  ARVCF  CTNNB1  ARHGAP32  ARHGAP39  ARF3  ARF5  DZANK1  AGAP2  GIT1  ABLIM1  ADAM22  CNTNAP1 Fig. 3 and Supplementary Table 2) .
While we observed that the core PSD scaffolds were highly correlated according to gene expression levels, they corresponded to a defined cellular localization and a defined PSD function. Therefore, we asked if this newly derived set of interactomes, which are functional heterogeneous, were also correlated according to gene expression with respect to the transcriptome background.
Analysis of mRNA levels using the Brainspan developmental transcriptome showed a higher correlation between protein interactors than with proteins expressed in brain PFC (Fig. 4b) , irrespective of localization, developmental stage or protein function. This suggests a general characteristic of and correlation between protein interactions and mRNA expression levels rather than a specific property of the PSD scaffolds.
We then analyzed and clustered protein interactomes by their similarity in protein composition. While Dlg4, Dlgap1 and Shank were tightly correlated, scaffold interactors showed a lower degree of clustering and were correlated in accordance with the interactome localization and developmental stage (Fig. 4c) . The largest correlation was observed in a number of adult-PSD interactomes corresponding to adaptor and enzymatic functions, such as Cyfip1, Tnik and Syngap1. These interactomes show a larger number of shared protein associations with Dlg4, Dlgap1 and Shank3, indicating a role for these adaptors and enzymes in the modulation of core-PSD scaffolds interactions.
We then determined the protein domain profile for individual protein complexes (Fig. 5 and Supplementary Table 6 ), considering protein domains that were present in at least four protein interactors in each protein complex, resulting in 355 domains from 966 proteins across protein complexes. Domain profiling confirmed the pattern observed for scaffold complexes (Figs. 3 and 5) , with adult PSD complexes showing an increase in protein interaction domains such as PDZ, SH3, PH and GuKc through development, reaching a peak at the PSD specialization. However, while scaffold complexes consistently presented a steady increase in protein-interaction, signaling and glutamate-receptor binding domains, PSD scaffold interactors associated a number of protein domains involved in DNA and/or RNA r e s o u r c e binding: RING, ZNF_C2H2 and SANT. These domains presented a steady decrease in abundance through development, which was not present in adult-PSD complexes ( Fig. 5 and Supplementary Dataset 2) . Therefore, scaffold interactors might better represent a collection of pairs of direct interactions without forming large protein complexes. Thus, while PSD scaffolds served as a template for the acquisition of functional domains, scaffold interactors were engaged in more variable protein associations and therefore represented a more heterogeneous set of functions through development and cellular localization.
Developmental PSD interactomes in complex brain disorders Several components of the PSD have been linked to a variety of brain diseases such as psychiatric disorders, ID and DD [23] [24] [25] [26] [27] [28] [29] [30] [31] . In particular, human genetics studies have recurrently proposed a role for PSD components in psychiatric disease. However, the differential distribution of common variants, rare variants and syndromic genes in these diseases makes it difficult to interpret the contribution of PSD components. To show how components of the PSD and their protein interactions can help our understanding of brain disease more generally, we incorporated published de novo coding mutations on exome-sequenced parent-proband trio cohorts from a variety of brain and psychiatric disorders. Published lists of de novo mutations were collected from ASD, DD, ID and SCZ databases. Specifically, we tested for an enrichment of protein-truncating and missense mutations (collectively termed 'nonsynonymous' mutations) in protein interaction networks, using the mutational model described in Genovese et al. 32 as our baseline expectation. We also examined de novo mutations from unaffected siblings of ASD and SCZ probands, as well as probands diagnosed with congenital heart disease but without any associated neurodevelopmental or syndromic phenotype ( Fig. 6a and Supplementary Table 7) . Across the spectrum of protein interaction networks that we generated, the enrichment in nonsynonymous de novo mutations was strongest in individuals diagnosed with DD or unresolved ID, in whom the majority of networks were significantly enriched in probands relative to model expectations ( Fig. 6a and Supplementary  Table 7) , followed closely by individuals diagnosed with ASD. Within these disorders, embryonic and early developmental protein complexes were more significant in DD and ID than in ASD (Fig. 6a,b and Supplementary Table 7) . Moreover, while the contribution to PSD and non-PSD complexes were equally significant for most disorders, PSD protein interactions were significantly more enriched in ID when compared to their non-PSD counterparts (Fig. 6a,b) . These results suggest some differential contribution of protein interactions from PSD components along development and cellular localization in these disorders (Fig. 6b) .
However, SCZ presented a different scenario, with little to no enrichment across the protein interactor networks and with only a modest enrichment observed relative to nonsyndromic congenital heart disease and unaffected siblings. In general, de novo protein truncating variants showed larger enrichment than missense mutations; however, the general patterns of significance across disease were consistent in both annotation types (Supplementary Table 7 ). The null result in SCZ, however, was not all that unexpected, as the burden of de novo mutations in SCZ is quite modest relative to other neuropsychiatric disorders, and the sample size we used was much lower than those for DD and ASD. In fact, when collapsing networks by developmental stage and PSD or non-PSD membership, we saw enrichment comparable with that in ASD but with less statistical power owing to the smaller number of trios (Fig. 6b) . Therefore, these results might reflect the genetic architecture of the disease rather than a particular characteristic of PSD protein interaction networks. As an example comparison, two of the 41 protein interactor sets, Tnik in adult PSD (P = 2.8 × 10 −4 ) and Dlg4 in P7 (P = 3.3 × 10 −4 ), were more significantly enriched in nonsynonymous mutations than in the activityregulated cytoskeleton (ARC) protein complex (P = 1.4 × 10 −3 ), a candidate gene set highlighted in both de novo single-nucleotide variant and copy-number variant studies of SCZ 23, 26, 32 (Supplementary  Table 5 ). Recently, an increased burden of ultrarare protein-altering variants in individuals with schizophrenia 32 has been shown. These ultrarare variants (URVs) are concentrated in neuronal expressed genes. We therefore asked whether particular protein interaction networks were enriched in SCZ URVs. We found that six of the 41 protein complexes were enriched in SCZ URVs (P < 0.05; Fig. 6c) , including different developmental stages of top PSD scaffold Dlg4 and lower PSD scaffold Shank3 (Fig. 6c) . Moreover, we also observed an enrichment in another Tnik, Shank3 and Dlg4 interactor: Cnksr2 (P = 1.9 × 10 −2 ). Cnksr2 complexes were enriched only in adult-PSD and not in non-PSD complexes. This PSD scaffold is incorporated into the PSD in late development and has a similar domain architecture to the Shank family of interactors (Supplementary Datasets 1 and 2) . Cnksr2 complexes were also enriched in nonsynonymous de novo Properties of nodes used in immunoisolation HPLC-MS/MS assays, indicating developmental stages and biochemical fractions in which nodes were found, node function, node degree (1-9 based on increasing number of connections) within scaffold network, and associations with Dlg4, Dlgap1 and Shank3 scaffolds.
r e s o u r c e mutations (P = 1.4 × 10 −3 ), similarly to ARC protein complexes. Moreover, CNKSR2 is candidate risk factor for SCZ as it is found within a single-gene, genome-wide significant locus, as determined by the Schizophrenia Working Group of the Psychiatric Genomics Consortium 33 . This suggests that a small number of adult-PSD complexes with interconnected protein interactions are associated with a variety of genetic signatures observed in SCZ.
Mutations in components of adult-PSD complexes
To explore whether mutations in highly connected components of PSD can affect the composition of PSD complexes enriched in brain disorders, we first clustered adult-PSD protein complexes and used two of the most highly connected genes, Tnik and Shank3 ( Fig. 7 and Supplementary Table 5) , with protein complexes enriched in multiple brain disorders (Fig. 6a,c) . To investigate how mutations Protein domain profiling of protein interactomes. Protein domain composition and enrichment in E14, adult, PSD and non-PSD fraction of protein complexes for scaffold interactors. Protein domains were manually curated from SMART and Pfam databases. Charts shows changes in the composition of protein domains between two different stages, PSD vs. non-PSD and/or E14 vs. adult, for several example complexes (*P < 0.05, hypergeometric test followed by Bonferroni correction). 'Significant enrichment' means that a particular domain is enriched in a protein complex compared to proteome-wide expectations and after being corrected for multiple comparisons. Full results can be found in Supplementary Table 4 .
r e s o u r c e in Tnik and Shank3 might disrupt protein interactions through the three layers of PSD complexes, we used Tnik knockout mice (Tnik −/− ) and a mouse line with a heterozygous deletion of Shank3 C-terminal region, Shank3 ∆C−/+ . We then isolated MAGUKs with a pan-MAGUK antibody and Dlgap1, and we used Shank3 protein complexes as an approximation for the distribution of changes in protein complexes across the three main layers of the PSD (Fig. 7a,b and Online Methods). Protein interactions and ratios for wild-type mice (WT) versus Tnik −/− and WT versus Shank3 ∆C−/+ were determined by nano-LC MS/MS.
A normalized spectral abundance factor was calculated for each protein 34 and used for comparison between different samples. A ratio ≥ 2 or ≤ 0.5 in triplicate samples was considered a biological change and confirmed by western blot (Fig. 7b,c, Supplementary Table 8 and Supplementary Fig. 4 ). To confirm that changes were a consequence of disruptions in protein interactions, we determined total protein levels in WT and mutant samples by western blot; no changes were observed in ratios of WT/mutant samples (Fig. 7b, Supplementary Table 7 and Supplementary Fig. 3) . We observed that mutations in highly Chart shows enrichment of protein-truncating and missense (nonsynonymous) mutations in protein interaction networks with respect to the baseline, as described in Genovese et al. 32 , which indicates the simulated multiple-testing correction (α = 0.05) level. Controls including de novo mutations from unaffected siblings (UNAFF-SIB) of ASD and SCZ probands, and probands diagnosed with congenital heart disease but without any associated neurodevelopmental or syndromic phenotype (CHD-NS) are included. Two-sided binomial exact test. The blacked dashed line represents the multiple-testing P-value threshold for all protein-interactor gene sets. The threshold is derived from simulations of de novo mutations using the mutation model, in which we kept the lowest P value seen in each simulation, with a cutoff at the fifth percentile of the these P values (i.e., family-wise error rate). r e s o u r c e connected components of the PSD protein-interaction network disrupted protein-protein interactions through the three scaffold-layers of the PSD (Fig. 7a-c and Supplementary Table 8 ). This group of proteins was highly enriched in psychiatric risk factors, with 45% described in genome-wide association studies of SCZ 33 , and they were also enriched in ASD, ID nonsynonymous de novo mutations and SCZ URVs. Moreover, we found that proteins with impaired association with PSD complexes contained SH3, PH, SAM, ANK and PDZ as the most common domain architectures (Supplementary Datasets 1  and 2 ). This suggests that mutations in components of the adult-PSD common to many of the complexes studied can also alter the pattern of protein interactions and/or localization of multiple candidate genes involved in different brain disorders.
Synaptic protein and pathways resource
To prioritize the significance of disease risk factors within their protein interaction and cellular landscape, we developed the software platform Psychiatric Protein/Pathway Resource (SyPPRes) available at http://neurocomplex.usc.edu. The software tool was built on the Phenolyzer tool 35 , which analyzes known gene-gene and genephenotype relationships from literature, then prioritizes candidate genes and generates interaction networks for each disease. By overlaying the molecular interaction information detected from our study on those inferred from existing biological knowledge, the SyPPRes tool uses these updated gene-gene relationships to prioritize genes with respect to different complex brain disorders, including ASD, SCZ, ID and epilepsy. For example, if a known ASD risk gene is located in the same protein complex with another gene previously not associated with ASD, this new gene will be prioritized as potentially contributing to ASD. The SyPPRes tool also allows user to specify specific genomic regions (such as peaks from genome-wide association studies) or gene list, to restrict the analysis to only a specific set of genes.
DISCUSSION
Starting with a developmental profile of the core-scaffold machinery of the PSD, we determined the molecular and cellular organization of PSD protein complexes and the context in which PSD components associated with brain disorders. We showed that the core PSD scaffold structure was already present at E14. This early structure starts to cluster components of the PSD and begins to define its future characteristics. However, while NMDAR subunits are already linked to MAGUKs and DLGAPs protein complexes, downstream components are kept in separate protein complexes organized by SHANKs. The core-NMDAR-MAGUK-DLGAP-SHANK three-layer scaffold structure was first observed at P7, while P7-P14 interactions represented a transition from E14 to adult complexes. We observed a continuous incorporation and expansion of functional groups with increased associations with glutamate receptors at the top layers and proteins with enzymatic activities incorporated through the middle and lower layer of scaffolds. Scaffold interactors form a more heterogeneous set of protein complexes when compared to core PSD scaffolds defining different sets of molecular complexes and cellular functions. Therefore, while the adult PSD protein interaction network is connected through a corescaffold component using localization specific hubs, a number of PSD scaffold interactors can also associate in protein networks enriched in 'housekeeping' protein interactions at early developmental stages that are not exclusive to neurons.
PSD signaling and complex brain disorders
A role for components of the PSD has been recurrently proposed in a number of psychiatric disorders. However, the current lack of information on PSD protein interactomes and their developmental and spatial profiles may generate an over-representation of individual adult protein complexes such as Arc and NMDAR 23, 26 ; this is particularly clear in SCZ genetics 23, 26, 32, 36 . Thus, to answer which complex(es) best capture disease association will require the characterization of a much wider range of complexes at multiple developmental time-points and characterization of how they behave under different patterns of synaptic stimulation 37 . Our data support a role for a relative small number of PSD protein complexes associated with the three main scaffold families (DLG, DLGAP and SHANK), with a core highly connected component enriched in psychiatric and ID candidate genes. These sets of molecules are observed in several psychiatric and brain disorder datasets [38] [39] [40] [41] [42] [43] and belong to the major signaling component of the PSD. Therefore, highly connected molecules within PSD interaction networks might not be associated to an individual protein complex but with the core protein interaction machinery of the PSD. This structure allows the connection of various components of the network 44 through their multidomain composition. Therefore, risk factors affecting signaling hubs may disrupt the domain architecture of the synaptic signaling network. Since many of these connections are linked to psychiatric disease, it is expected that the network may be disrupted by mutations at different components. Therefore, kinases like Tnik and scaffolds such as Shank3 might represent two ends of the spectrum of adult PSD signaling complexes. While scaffolds can cluster risk factors through its interaction modules, kinases and phosphatases can dynamically regulate the interactions of these modules through protein phosphorylation.
As the list of psychiatric and brain disorder risk factors is likely to continue growing, it will be important to determine whether the combination of risk factors in synaptic components indicates only a general deficit in PSD signaling or whether these components integrate into specific signaling components of the PSD signaling machinery. Beyond addressing molecular mechanisms in determined risk pathways, future studies will need to address how components of protein interaction networks that are not physically connected contribute to an individual's susceptibility to brain disorders. It will be important to define whether risk factors accumulate within one risk pathway or need to be combined within different spatiotemporal networks. This latter option raises the possibility that a combinatorial profile of risk factors, distributed along biological networks, might contribute to the heterogeneity and overlap within disorders 45 . Thus, determining the cellular networks in which risk factors are functionally active with tools such as SyPPRes may help to define disease risk scores and develop strategies to stratify individuals with regard to their vulnerability to psychiatric and other brain disorders.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. r e s o u r c e F.S. and M.P.C. supervised analysis; F.S., K.W. and M.P.C. designed experiments and analysis; J.L., B.W., F.S. and M.P.C. and wrote the manuscript; M.P.C. supervised the project.
We used a Bonferroni correction to adjust for multiple testing. That is, only domains with P < α/T were considered significant, where T is the number of different domains analyzed across all reported complexes (n = 320).
Testing for co-expression using the Brainspan database. For each gene complex we considered three parameters: (i) number of genes in the complex, (ii) the minimum and maximum expression of genes in the complex and (iii) the correspondent age (lifespan) where the complex was discovered.
1) C_k = the number of genes in the complex 2) C_min, C_max = the minimum and maximum expression of genes in the complex 3) C_L = the relevant age (lifespan) where the complex was discovered For a given C_L the average pairwise squared sample correlation (ASC) was calculated across all genes in the complex. Additionally, pseudocomplexes were created by randomly sampling k genes from C_L, without replacement, with expression values between C_min and C_max. In each case, 10,000 trials were performed and the ASC across each pseudocomplex was calculated to provide the empirical P value.
We used 4-7 individuals per developmental stage, analyzing up to 16 regions per individual. Every sample was a region from an individual and we analyzed correlations across individuals across the whole data set (person and region) for each gene in the cluster. We calculated min/max expressions in each cluster, randomly sampled more groups with min/max bounds equal to our cluster and calculated average pairwise correlations. Variation between regions was not significant and therefore allowed us to use different brain regions per individual to increase the sample size. Adult (young adult to adult): 111 samples from 7 individuals and 16 regions; A1C = 7, AMY = 7, CBC = 7, DFC = 7, HIP = 7, IPC = 7, ITC = 7, M1C = 7, MD = 7, MFC = 6, OFC = 7, S1C = 7, STC = 7, STR = 7, V1C = 7 and VFC = 7.
DFC, dorsolateral prefrontal cortex; VFC, ventrolateral prefrontal cortex; OFC, orbital frontal cortex; IPC, posteroventral (inferior) parietal cortex; ITC, inferolateral temporal cortex (area TEv and area 20); A1C, primary auditory cortex (core); AMY, amygdaloid complex; CBC, cerebellar cortex; HIP, hippocampus (hippocampal formation); M1C, primary motor cortex (area M1 and area 4); MFC, anterior (rostral) cingulate (medial prefrontal) cortex; MD, mediodorsal nucleus of thalamus; S1C, primary somatosensory cortex (area S1 and areas 1-3); STR, striatum; V1C, primary visual cortex (striate cortex and area V1/17).
Human genetics data sets and enrichment analysis. De novo coding mutations on exome-sequenced parent-proband trio cohorts from SCZ, ASD, DD and ID were used for analysis, using probands from unaffected siblings and from probands diagnosed with congenital heart disease but without associated neurodevelopmental or syndromic phenotypes (CHD-NS) as controls. We also analyzed de novo protein truncating variants (PTVs) found in patients with SCZ 32 .
We collected de novo mutations from SCZ (7 studies), ASD (6 studies), DD (2 studies), ID (3 studies) and CHD (2 studies; Supplementary Table 7) . Unaffected siblings and control trios were also available from a subset of these studies (8 studies). For CHD, we split the full CHD cohort into those presenting with additional disease phenotypes (syndromic CHD or CHD-S) and those with isolated CHD phenotypes (nonsyndromic CHD or CHD-NS). All de novo mutation lists were reannotated using Variant Effect Predictor (VEP) version 81 (refs. 49-51) . We filtered de novo mutations present in the nonpsychiatric cohort of the Exome Aggregation Consortium (ExAC), which improved our likelihood of selecting pathogenic variants, as evidenced by the mutation burden in disease cohorts relative to controls being restricted to variants absent from ExAC 49 . Gene set enrichment was tested using a two-sided binomial exact test, with the theoretical expectation determined by the aggregated mutation expectation in the gene set 47 . This test explicitly controlled for the enrichment in mutational burden, as enrichment was relative to the total number of mutations observed rather than to the number of trios analyzed. We focused our enrichment tests on protein-truncating mutations, missense mutations and the combination of both (nonsynonymous mutations). To correct for multiple testing, we estimated the family-wise error rate across all protein networks using simulated de novo variants. Each simulation randomly drew mutations for each mutation class using per-gene probabilities from the mutation model, and the family-wise error used was the fifth percentile of minimum P values across all simulations. The multiple testing correction thresholds for P value significance are as follows: PTV = 2 × 10 −3 , missense = 9 × 10 −4 and nonsynonymous = 1.4 × 10 −3 . (References are listed in Supplementary Table 7 under the "Summary information" tab).
SyPPRes. The phenotype-based prioritization of candidate genes for human diseases within protein interactions and human whole-genome and whole-exome sequencing studies is integrated within the Phenolyzer platform. Description of the algorithm and scoring system is described in Yang et al. 35 . SyPPRes: http://neurocomplex.usc.edu/.
Statistics. Protein domain enrichment was tested using the hypergeometric test, followed by the Bonferroni correction for multiple comparisons. Enrichment of protein complexes in proteins harboring de novo mutations was carried out using the two-sided binomial exact test and corrected for multiple comparisons using an estimated family-wise error rate to account for all protein complexes analyzed. Enrichment in SCZ URVs was completed using both linear and logistic regression models. Significance of western blot quantitation was tested using two-tailed unpaired t-tests, and the results are expressed as mean ± s.e.m. When applicable, equal variance was formally tested using the F-test. Data distribution was assumed to be normal, but this was not formally tested. No statistical methods were used to predetermine sample size, but our sample sizes are similar to those reports in previous publications 3, 10, 37, 52, 53 . Data collection and analysis were not performed blind to the conditions of the experiments. No randomization was used. No data points were excluded from the analyses performed. A Supplementary methods checklist is available.
Data availability. All data generated or analyzed during this study are included in this published article (and its Supplementary Information files). Files can be obtained from the ProteomeXchange Consortium via the PRIDE partner repository (PMID: 27683222) with the data set identifier PXD006277. Data sets for individual protein complexes can also be downloaded at: SyPPRes (http://neurocomplex.usc.edu/). Accession codes. Mass spectrometry raw files have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (PMID: 27683222) with the data set identifier PXD006277.
code availability. The latest version for SyPPRes (Phenolyzer) command line tool is available at: https://github.com/WangGenomicsLab/phenolyzer.
